Literature DB >> 30078504

Validation of PROMIS emotional distress short form scales for cervical cancer.

Justin Wilford1, Kathryn Osann2, Susie Hsieh2, Bradley Monk3, Edward Nelson4, Lari Wenzel5.   

Abstract

OBJECTIVES: Cervical cancer patients are at high risk for emotional distress. In this study we evaluate the PROMIS emotional distress-Depression and -Anxiety Short Forms for assessing depression and anxiety in a cervical cancer population.
METHODS: A 15-item questionnaire was used in a cervical cancer biobehavioral randomized clinical trial, testing psychosocial telephone counseling (PTC) against usual care (UC). It was administered to 204 patients prior to randomization, four months post-enrollment, and nine months post-enrollment, together with legacy measures of depression. The short forms were evaluated in patients participating in this study over three time points for internal consistency, convergent validity, and responsiveness to change over time.
RESULTS: Overall, 45% and 47% of patients scored in the moderate to severe range for anxiety and depression, respectively. Internal consistency coefficients were ≥ 0.95 at baseline, 4 months, and 9 months for depression and anxiety. The average inter-item correlation was 0.65 and 0.73 at baseline assessment for depression and anxiety, respectively. The depression short form T-score was correlated with legacy distress scales ranging from 0.44-0.76, and the anxiety short form ranging from 0.45-0.78. The depression short form demonstrated sensitivity to change as patients randomized to the counseling intervention reported greater improvement over time in depression (p = 0.014), and a nonsignificant improvement in anxiety, compared to the patients receiving usual care.
CONCLUSIONS: The PROMIS depression and anxiety short forms reliably and validly assess cervical cancer-specific emotional distress, capture salient features of distress in this population, and perform as well or better than legacy measures.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anxiety; Cervical cancer; Depression; Patient-reported outcomes

Mesh:

Year:  2018        PMID: 30078504      PMCID: PMC6171766          DOI: 10.1016/j.ygyno.2018.07.022

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  38 in total

1.  A new psychosocial screening instrument for use with cancer patients.

Authors:  J Zabora; K BrintzenhofeSzoc; P Jacobsen; B Curbow; S Piantadosi; C Hooker; A Owens; L Derogatis
Journal:  Psychosomatics       Date:  2001 May-Jun       Impact factor: 2.386

2.  United States Population-Based Estimates of Patient-Reported Outcomes Measurement Information System Symptom and Functional Status Reference Values for Individuals With Cancer.

Authors:  Roxanne E Jensen; Arnold L Potosky; Carol M Moinpour; Tania Lobo; David Cella; Elizabeth A Hahn; David Thissen; Ashley Wilder Smith; Jaeil Ahn; George Luta; Bryce B Reeve
Journal:  J Clin Oncol       Date:  2017-04-20       Impact factor: 44.544

3.  Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).

Authors:  Richard T Penson; Helen Q Huang; Lari B Wenzel; Bradley J Monk; Sharon Stockman; Harry J Long; Lois M Ramondetta; Lisa M Landrum; Ana Oaknin; Thomas J A Reid; Mario M Leitao; Michael Method; Helen Michael; Krishnansu S Tewari
Journal:  Lancet Oncol       Date:  2015-01-29       Impact factor: 41.316

4.  Quality of life in long-term cervical cancer survivors.

Authors:  Lari Wenzel; Israel DeAlba; Rana Habbal; Brenda Coffey Kluhsman; Diane Fairclough; Linda U Krebs; Hoda Anton-Culver; Ross Berkowitz; Noreen Aziz
Journal:  Gynecol Oncol       Date:  2005-05       Impact factor: 5.482

Review 5.  Cervical cancer survivorship: long-term quality of life and social support.

Authors:  Krista S Pfaendler; Lari Wenzel; Mindy B Mechanic; Kristine R Penner
Journal:  Clin Ther       Date:  2015-01-01       Impact factor: 3.393

6.  Improved survival with bevacizumab in advanced cervical cancer.

Authors:  Krishnansu S Tewari; Michael W Sill; Harry J Long; Richard T Penson; Helen Huang; Lois M Ramondetta; Lisa M Landrum; Ana Oaknin; Thomas J Reid; Mario M Leitao; Helen E Michael; Bradley J Monk
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

7.  Setting standards for severity of common symptoms in oncology using the PROMIS item banks and expert judgment.

Authors:  David Cella; Seung Choi; Sofia Garcia; Karon F Cook; Sarah Rosenbloom; Jin-Shei Lai; Donna Surges Tatum; Richard Gershon
Journal:  Qual Life Res       Date:  2014-06-18       Impact factor: 4.147

8.  Factors associated with poor quality of life among cervical cancer survivors: implications for clinical care and clinical trials.

Authors:  Kathryn Osann; Susie Hsieh; Edward L Nelson; Bradley J Monk; Dana Chase; David Cella; Lari Wenzel
Journal:  Gynecol Oncol       Date:  2014-09-03       Impact factor: 5.482

9.  Quality of life and disparities among long-term cervical cancer survivors.

Authors:  Howard P Greenwald; Ruth McCorkle; Kathy Baumgartner; Carolyn Gotay; Anne Victoria Neale
Journal:  J Cancer Surviv       Date:  2014-04-05       Impact factor: 4.442

Review 10.  Depressive Spectrum Disorders in Cancer: Diagnostic Issues and Intervention. A Critical Review.

Authors:  Rosangela Caruso; Maria GiuliaNanni; Michelle B Riba; Silvana Sabato; Luigi Grassi
Journal:  Curr Psychiatry Rep       Date:  2017-06       Impact factor: 5.285

View more
  2 in total

1.  A Formative Evaluation of Patient and Family Caregiver Perspectives on Early Palliative Care in Chronic Obstructive Pulmonary Disease across Disease Severity.

Authors:  Anand S Iyer; J Nicholas Dionne-Odom; Stephanie M Ford; Sheri L Crump Tims; Elizabeth D Sockwell; Nataliya V Ivankova; Cynthia J Brown; Rodney O Tucker; Mark T Dransfield; Marie A Bakitas
Journal:  Ann Am Thorac Soc       Date:  2019-08

2.  Longitudinal exploration of cancer-related cognitive impairment in patients with newly diagnosed aggressive lymphoma: protocol for a feasibility study.

Authors:  Priscilla Gates; Karla Gough; Haryana Dhillon; Carlene Wilson; Eliza Hawkes; Vincent Dore; Yuliya Perchyonok; Christopher C Rowe; Adam K Walker; Janette L Vardy; Michiel de Ruiter; Meinir Krishnasamy
Journal:  BMJ Open       Date:  2020-09-29       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.